-
公开(公告)号：US07465825B2
公开(公告)日：2008-12-16
申请号：US11283437
申请日：2005-11-18
IPC分类号： C07C229/00 , C07D333/00 , C07D307/91 , A01N43/12 , A01N43/08
CPC分类号： C07D307/79 , C07C271/22 , C07C311/29 , C07C317/14 , C07C317/32 , C07C323/52 , C07C323/65 , C07C2603/74 , C07D307/91
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 公开了式（A）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US07329680B2
公开(公告)日：2008-02-12
申请号：US10835818
申请日：2004-04-30
IPC分类号： C07D277/38 , A61K31/425
CPC分类号： C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D417/10 , C07D417/12
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 本发明涉及式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抵抗或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US20060100251A1
公开(公告)日：2006-05-11
申请号：US11262423
申请日：2005-10-28
IPC分类号： A61K31/44 , A61K31/195 , C07D213/55 , C07C311/42
CPC分类号： C07C311/21 , C07C69/65 , C07C311/29 , C07D213/55
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
摘要翻译： 本发明涉及式I化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。 这些化合物包括可用于治疗糖尿病和其它PTP-1B介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶（PTP-1B）的抑制剂。 本发明的化合物也可用于治疗上述病症的药物组合物和方法。
-
公开(公告)号：US20060094747A1
公开(公告)日：2006-05-04
申请号：US11261019
申请日：2005-10-28
申请人： Michael Van Zandt , Darren Whitehouse , Kerry Combs , Shaojing Hu
发明人： Michael Van Zandt , Darren Whitehouse , Kerry Combs , Shaojing Hu
IPC分类号： A61K31/4745 , A61K31/416 , A61K31/381 , A61K31/423 , A61K31/343 , C07D333/76 , C07D333/72 , C07D471/02
CPC分类号： C07D307/79 , C07C69/65 , C07C69/736 , C07C69/738 , C07C309/65 , C07C2601/16 , C07D307/91
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
摘要翻译： 本发明涉及式I化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。 这些化合物包括可用于治疗糖尿病和其它PTP-1B介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶（PTP-1B）的抑制剂。 本发明的化合物也可用于治疗上述病症的药物组合物和方法。
-
公开(公告)号：US20130203672A1
公开(公告)日：2013-08-08
申请号：US13698819
申请日：2010-05-17
申请人： Shaojing Hu , Fenlai Tan , Yanping Wang , Cunbo Ma , Yunyan Hu , Hong Cao , Xiangdong Zhao , Wei Long , Yinxiang Wang , Lieming Ding
发明人： Shaojing Hu , Fenlai Tan , Yanping Wang , Cunbo Ma , Yunyan Hu , Hong Cao , Xiangdong Zhao , Wei Long , Yinxiang Wang , Lieming Ding
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K9/0019 , A61K38/00
摘要： The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.
摘要翻译： 本发明涉及胰高血糖素样肽的新型类似物和可用于上调哺乳动物胰岛素表达和治疗糖尿病的组合物。 特别地，这些肽衍生物具有肽模拟接头并且提供用于治疗糖尿病和其它促胰岛素肽相关疾病，胃肠功能和与胰高血糖素水平相关的活性的长期作用。
-
公开(公告)号：US07498356B2
公开(公告)日：2009-03-03
申请号：US11283456
申请日：2005-11-18
IPC分类号： A61K31/343 , C07D307/91
CPC分类号： C07D307/79 , C07D209/08 , C07D215/12 , C07D307/80 , C07D307/91 , C07D317/56 , C07D333/76 , C07D405/04 , C07D405/12 , C07D417/04
摘要： Disclosed are compound and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compound of the invention include inhibitors of protein tyrosine phosphatase, in particular protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising aforementioned conditions using such compounds.
摘要翻译： 公开了式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含使用这些化合物的上述条件的药物组合物。
-
公开(公告)号：US07358364B2
公开(公告)日：2008-04-15
申请号：US10823842
申请日：2004-04-14
IPC分类号： C07D471/00 , C07D498/00 , C07D513/00 , C07D405/00 , C07D307/87
CPC分类号： C07D263/57 , C07C69/736 , C07D209/08 , C07D277/66 , C07D307/80 , C07D307/91 , C07D307/92 , C07D405/10 , C07D417/04 , C07D471/04
摘要： The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
摘要翻译： 本发明涉及式（I）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。 这些化合物包括可用于治疗糖尿病和其它PTP-1B介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶（PTP-1B）的抑制剂。 本发明的化合物也可用于治疗上述病症的药物组合物和方法。
-
公开(公告)号：US20060122257A1
公开(公告)日：2006-06-08
申请号：US11283437
申请日：2005-11-18
IPC分类号： A61K31/381 , A61K31/343 , A61K31/198 , C07C235/32 , C07D333/76
CPC分类号： C07D307/79 , C07C271/22 , C07C311/29 , C07C317/14 , C07C317/32 , C07C323/52 , C07C323/65 , C07C2603/74 , C07D307/91
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
-
公开(公告)号：US20050004369A1
公开(公告)日：2005-01-06
申请号：US10835924
申请日：2004-04-30
IPC分类号： C07C311/19 , C07C311/29 , C07D209/08 , C07D233/62 , C07D277/38 , C07D307/79 , C07D307/80 , C07D307/81 , C07D307/91 , C07D401/04 , C07D263/02
CPC分类号： C07D307/79 , C07C311/19 , C07C311/29 , C07D209/08 , C07D307/80 , C07D307/81 , C07D307/91 , C07D401/04
摘要： Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
摘要翻译： 公开了式（A）的化合物和药学上可接受的盐：其可用于治疗与胰岛素抵抗，瘦素抗性或高血糖相关的代谢紊乱。 本发明的化合物包括可用于治疗糖尿病和其它PTP介导的疾病如癌症，神经变性疾病等的蛋白质酪氨酸磷酸酶抑制剂，特别是蛋白质酪氨酸磷酸酶-1B（PTP-1B）。 还公开了包含本发明化合物的药物组合物和使用这些化合物治疗上述病症的方法。
-
公开(公告)号：US20130053304A1
公开(公告)日：2013-02-28
申请号：US13643840
申请日：2011-04-29
申请人： Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
发明人： Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
IPC分类号： A61K38/26 , A61P3/10 , A61P3/08 , A61P3/04 , A61P9/12 , A61P1/04 , A61P25/00 , A61P9/10 , A61P9/00 , A61P7/02 , A61P1/00 , C07K14/605 , A61P3/06
CPC分类号： C07K14/605 , A61K38/00
摘要： Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.
摘要翻译： 本发明提供如下式所示的胰高血糖素样肽-1（GLP-1）类似物，其中X选自甘氨酸和甘氨酰胺。 GLP-1类似物相对于序列GLP-1具有位置8的非蛋白原性氨基酸残基，并且用包含两个酸性基团的部分酰化至位置26的赖氨酸残基。GLP-1类似物对 二肽基肽酶IV，以使体内延长半衰期。 还提供了GLP-1类似物在征服血糖中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.026 秒)
